Funder
National Institute on Aging
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference28 articles.
1. Centers for Medicare & Medicaid Services. Monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. Decision Memo 2022 April 7, 2022. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=305. Accessed 28 Apr 2022.
2. Terry M. Biogen’s Aduhelm faces more obstacles as some insurers balking at paying for drug. 2021. https://www.biospace.com/article/biogen-s-aduhelm-faces-more-obstacles-as-some-insurers-balking-at-paying-for-drug/. Accessed 5 Mar 2022.
3. Hlavka JP, Yu JC, Goldman DP, Lakdawalla DN. The economics of alternative payment models for pharmaceuticals. Eur J Health Econ. 2021;22(4):559–69.
4. Bohm N, Bermingham S, Grimsey Jones F, Goncalves-Bradley DC, et al. The challenges of outcomes-based contract implementation for medicines in Europe. Pharmacoeconomics. 2022;40(1):13–29.
5. Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30(12):2329–37.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献